What question did this study set out to answer?

This report aims to highlight the occurrence of myocarditis due to bortezomib in a patient with multiple myeloma.

February 27, 2026Open Access

Bortezomib-Induced Myocarditis in a Patient With Multiple Myeloma

Resultado clave

Early recognition, stopping bortezomib, and timely heart failure treatment enable full recovery from bortezomib-induced myocarditis in multiple myeloma patients.

Puntos clave

This report aims to highlight the occurrence of myocarditis due to bortezomib in a patient with multiple myeloma.
Documented patient case with bortezomib treatment
Monitored for symptoms of myocarditis
Evaluated heart function and therapy response
Early recognition of myocarditis led to drug withdrawal.
Timely heart failure therapy facilitated full recovery.

PICO estructurado

Población

A patient with multiple myeloma

Intervención

Bortezomib withdrawal and heart failure therapy

Early recognition, prompt drug withdrawal, and timely heart failure therapy are essential for full recovery from bortezomib-induced myocarditis.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Early recognition, prompt drug withdrawal, and timely heart failure therapy are essential to ensure full recovery.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Dominguez-Linares et al. (Sun,) reported a other. Early recognition, stopping bortezomib, and timely heart failure treatment enable full recovery from bortezomib-induced myocarditis in multiple myeloma patients.

synapsesocial.com/papers/69a1344fed1d949a99abe240 https://doi.org/https://doi.org/10.1016/j.jaccas.2026.107027

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo